The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral GLP-1 Agonist Market Research Report 2025
Synopsis
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
The global Oral GLP-1 Agonist market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oral GLP-1 Agonist is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oral GLP-1 Agonist is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oral GLP-1 Agonist include Novo Nordisk, Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oral GLP-1 Agonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral GLP-1 Agonist.
The Oral GLP-1 Agonist market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oral GLP-1 Agonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral GLP-1 Agonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
Segment by Type
Semaglutide
Non-peptide
Segment by Application
Diabetes
Obesity
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral GLP-1 Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral GLP-1 Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
The global Oral GLP-1 Agonist market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oral GLP-1 Agonist is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oral GLP-1 Agonist is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oral GLP-1 Agonist include Novo Nordisk, Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oral GLP-1 Agonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral GLP-1 Agonist.
The Oral GLP-1 Agonist market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oral GLP-1 Agonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral GLP-1 Agonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
Segment by Type
Semaglutide
Non-peptide
Segment by Application
Diabetes
Obesity
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral GLP-1 Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral GLP-1 Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oral GLP-1 Agonist Market Overview
1.1 Product Definition
1.2 Oral GLP-1 Agonist by Type
1.2.1 Global Oral GLP-1 Agonist Market Value Comparison by Type (2024-2030)
1.2.2 Semaglutide
1.2.3 Non-peptide
1.3 Oral GLP-1 Agonist by Application
1.3.1 Global Oral GLP-1 Agonist Market Value by Application (2024-2030)
1.3.2 Diabetes
1.3.3 Obesity
1.4 Global Oral GLP-1 Agonist Market Size Estimates and Forecasts
1.4.1 Global Oral GLP-1 Agonist Revenue 2019-2030
1.4.2 Global Oral GLP-1 Agonist Sales 2019-2030
1.4.3 Global Oral GLP-1 Agonist Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral GLP-1 Agonist Market Competition by Manufacturers
2.1 Global Oral GLP-1 Agonist Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral GLP-1 Agonist Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral GLP-1 Agonist Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Oral GLP-1 Agonist, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral GLP-1 Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral GLP-1 Agonist, Product Type & Application
2.7 Global Key Manufacturers of Oral GLP-1 Agonist, Date of Enter into This Industry
2.8 Global Oral GLP-1 Agonist Market Competitive Situation and Trends
2.8.1 Global Oral GLP-1 Agonist Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oral GLP-1 Agonist Players Market Share by Revenue
2.8.3 Global Oral GLP-1 Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oral GLP-1 Agonist Market Scenario by Region
3.1 Global Oral GLP-1 Agonist Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral GLP-1 Agonist Sales by Region: 2019-2030
3.2.1 Global Oral GLP-1 Agonist Sales by Region: 2019-2024
3.2.2 Global Oral GLP-1 Agonist Sales by Region: 2025-2030
3.3 Global Oral GLP-1 Agonist Revenue by Region: 2019-2030
3.3.1 Global Oral GLP-1 Agonist Revenue by Region: 2019-2024
3.3.2 Global Oral GLP-1 Agonist Revenue by Region: 2025-2030
3.4 North America Oral GLP-1 Agonist Market Facts & Figures by Country
3.4.1 North America Oral GLP-1 Agonist Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral GLP-1 Agonist Sales by Country (2019-2030)
3.4.3 North America Oral GLP-1 Agonist Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral GLP-1 Agonist Market Facts & Figures by Country
3.5.1 Europe Oral GLP-1 Agonist Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral GLP-1 Agonist Sales by Country (2019-2030)
3.5.3 Europe Oral GLP-1 Agonist Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral GLP-1 Agonist Market Facts & Figures by Region
3.6.1 Asia Pacific Oral GLP-1 Agonist Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral GLP-1 Agonist Sales by Region (2019-2030)
3.6.3 Asia Pacific Oral GLP-1 Agonist Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral GLP-1 Agonist Market Facts & Figures by Country
3.7.1 Latin America Oral GLP-1 Agonist Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral GLP-1 Agonist Sales by Country (2019-2030)
3.7.3 Latin America Oral GLP-1 Agonist Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oral GLP-1 Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral GLP-1 Agonist Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral GLP-1 Agonist Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral GLP-1 Agonist Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral GLP-1 Agonist Sales by Type (2019-2030)
4.1.1 Global Oral GLP-1 Agonist Sales by Type (2019-2024)
4.1.2 Global Oral GLP-1 Agonist Sales by Type (2025-2030)
4.1.3 Global Oral GLP-1 Agonist Sales Market Share by Type (2019-2030)
4.2 Global Oral GLP-1 Agonist Revenue by Type (2019-2030)
4.2.1 Global Oral GLP-1 Agonist Revenue by Type (2019-2024)
4.2.2 Global Oral GLP-1 Agonist Revenue by Type (2025-2030)
4.2.3 Global Oral GLP-1 Agonist Revenue Market Share by Type (2019-2030)
4.3 Global Oral GLP-1 Agonist Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral GLP-1 Agonist Sales by Application (2019-2030)
5.1.1 Global Oral GLP-1 Agonist Sales by Application (2019-2024)
5.1.2 Global Oral GLP-1 Agonist Sales by Application (2025-2030)
5.1.3 Global Oral GLP-1 Agonist Sales Market Share by Application (2019-2030)
5.2 Global Oral GLP-1 Agonist Revenue by Application (2019-2030)
5.2.1 Global Oral GLP-1 Agonist Revenue by Application (2019-2024)
5.2.2 Global Oral GLP-1 Agonist Revenue by Application (2025-2030)
5.2.3 Global Oral GLP-1 Agonist Revenue Market Share by Application (2019-2030)
5.3 Global Oral GLP-1 Agonist Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Oral GLP-1 Agonist Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Oral GLP-1 Agonist Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Oral GLP-1 Agonist Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly Oral GLP-1 Agonist Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral GLP-1 Agonist Industry Chain Analysis
7.2 Oral GLP-1 Agonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral GLP-1 Agonist Production Mode & Process
7.4 Oral GLP-1 Agonist Sales and Marketing
7.4.1 Oral GLP-1 Agonist Sales Channels
7.4.2 Oral GLP-1 Agonist Distributors
7.5 Oral GLP-1 Agonist Customers
8 Oral GLP-1 Agonist Market Dynamics
8.1 Oral GLP-1 Agonist Industry Trends
8.2 Oral GLP-1 Agonist Market Drivers
8.3 Oral GLP-1 Agonist Market Challenges
8.4 Oral GLP-1 Agonist Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Oral GLP-1 Agonist Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oral GLP-1 Agonist Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Oral GLP-1 Agonist Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oral GLP-1 Agonist Sales (Units) of Key Manufacturers (2019-2024)
Table 5. Global Oral GLP-1 Agonist Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oral GLP-1 Agonist Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oral GLP-1 Agonist Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oral GLP-1 Agonist Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oral GLP-1 Agonist, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral GLP-1 Agonist, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral GLP-1 Agonist, Product Type & Application
Table 12. Global Key Manufacturers of Oral GLP-1 Agonist, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral GLP-1 Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral GLP-1 Agonist as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral GLP-1 Agonist Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oral GLP-1 Agonist Sales by Region (2019-2024) & (Units)
Table 18. Global Oral GLP-1 Agonist Sales Market Share by Region (2019-2024)
Table 19. Global Oral GLP-1 Agonist Sales by Region (2025-2030) & (Units)
Table 20. Global Oral GLP-1 Agonist Sales Market Share by Region (2025-2030)
Table 21. Global Oral GLP-1 Agonist Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oral GLP-1 Agonist Revenue Market Share by Region (2019-2024)
Table 23. Global Oral GLP-1 Agonist Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oral GLP-1 Agonist Revenue Market Share by Region (2025-2030)
Table 25. North America Oral GLP-1 Agonist Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oral GLP-1 Agonist Sales by Country (2019-2024) & (Units)
Table 27. North America Oral GLP-1 Agonist Sales by Country (2025-2030) & (Units)
Table 28. North America Oral GLP-1 Agonist Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oral GLP-1 Agonist Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oral GLP-1 Agonist Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oral GLP-1 Agonist Sales by Country (2019-2024) & (Units)
Table 32. Europe Oral GLP-1 Agonist Sales by Country (2025-2030) & (Units)
Table 33. Europe Oral GLP-1 Agonist Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oral GLP-1 Agonist Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oral GLP-1 Agonist Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oral GLP-1 Agonist Sales by Region (2019-2024) & (Units)
Table 37. Asia Pacific Oral GLP-1 Agonist Sales by Region (2025-2030) & (Units)
Table 38. Asia Pacific Oral GLP-1 Agonist Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oral GLP-1 Agonist Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oral GLP-1 Agonist Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oral GLP-1 Agonist Sales by Country (2019-2024) & (Units)
Table 42. Latin America Oral GLP-1 Agonist Sales by Country (2025-2030) & (Units)
Table 43. Latin America Oral GLP-1 Agonist Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oral GLP-1 Agonist Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Oral GLP-1 Agonist Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Oral GLP-1 Agonist Sales by Country (2019-2024) & (Units)
Table 47. Middle East and Africa Oral GLP-1 Agonist Sales by Country (2025-2030) & (Units)
Table 48. Middle East and Africa Oral GLP-1 Agonist Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Oral GLP-1 Agonist Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oral GLP-1 Agonist Sales (Units) by Type (2019-2024)
Table 51. Global Oral GLP-1 Agonist Sales (Units) by Type (2025-2030)
Table 52. Global Oral GLP-1 Agonist Sales Market Share by Type (2019-2024)
Table 53. Global Oral GLP-1 Agonist Sales Market Share by Type (2025-2030)
Table 54. Global Oral GLP-1 Agonist Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oral GLP-1 Agonist Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oral GLP-1 Agonist Revenue Market Share by Type (2019-2024)
Table 57. Global Oral GLP-1 Agonist Revenue Market Share by Type (2025-2030)
Table 58. Global Oral GLP-1 Agonist Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oral GLP-1 Agonist Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oral GLP-1 Agonist Sales (Units) by Application (2019-2024)
Table 61. Global Oral GLP-1 Agonist Sales (Units) by Application (2025-2030)
Table 62. Global Oral GLP-1 Agonist Sales Market Share by Application (2019-2024)
Table 63. Global Oral GLP-1 Agonist Sales Market Share by Application (2025-2030)
Table 64. Global Oral GLP-1 Agonist Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oral GLP-1 Agonist Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oral GLP-1 Agonist Revenue Market Share by Application (2019-2024)
Table 67. Global Oral GLP-1 Agonist Revenue Market Share by Application (2025-2030)
Table 68. Global Oral GLP-1 Agonist Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oral GLP-1 Agonist Price (US$/Unit) by Application (2025-2030)
Table 70. Novo Nordisk Company Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Oral GLP-1 Agonist Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Novo Nordisk Oral GLP-1 Agonist Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly Oral GLP-1 Agonist Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Eli Lilly Oral GLP-1 Agonist Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Key Raw Materials Lists
Table 81. Raw Materials Key Suppliers Lists
Table 82. Oral GLP-1 Agonist Distributors List
Table 83. Oral GLP-1 Agonist Customers List
Table 84. Oral GLP-1 Agonist Market Trends
Table 85. Oral GLP-1 Agonist Market Drivers
Table 86. Oral GLP-1 Agonist Market Challenges
Table 87. Oral GLP-1 Agonist Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
Table 91. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oral GLP-1 Agonist
Figure 2. Global Oral GLP-1 Agonist Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oral GLP-1 Agonist Market Share by Type: 2023 & 2030
Figure 4. Semaglutide Product Picture
Figure 5. Non-peptide Product Picture
Figure 6. Global Oral GLP-1 Agonist Market Value by Application (2024-2030) & (US$ Million)
Figure 7. Global Oral GLP-1 Agonist Market Share by Application: 2023 & 2030
Figure 8. Diabetes
Figure 9. Obesity
Figure 10. Global Oral GLP-1 Agonist Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Oral GLP-1 Agonist Market Size (2019-2030) & (US$ Million)
Figure 12. Global Oral GLP-1 Agonist Sales (2019-2030) & (Units)
Figure 13. Global Oral GLP-1 Agonist Average Price (US$/Unit) & (2019-2030)
Figure 14. Oral GLP-1 Agonist Report Years Considered
Figure 15. Oral GLP-1 Agonist Sales Share by Manufacturers in 2023
Figure 16. Global Oral GLP-1 Agonist Revenue Share by Manufacturers in 2023
Figure 17. Global 5 and 10 Largest Oral GLP-1 Agonist Players: Market Share by Revenue in Oral GLP-1 Agonist in 2023
Figure 18. Oral GLP-1 Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 19. Global Oral GLP-1 Agonist Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Oral GLP-1 Agonist Sales Market Share by Country (2019-2030)
Figure 21. North America Oral GLP-1 Agonist Revenue Market Share by Country (2019-2030)
Figure 22. United States Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Oral GLP-1 Agonist Sales Market Share by Country (2019-2030)
Figure 25. Europe Oral GLP-1 Agonist Revenue Market Share by Country (2019-2030)
Figure 26. Germany Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Oral GLP-1 Agonist Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Oral GLP-1 Agonist Revenue Market Share by Region (2019-2030)
Figure 33. China Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Latin America Oral GLP-1 Agonist Sales Market Share by Country (2019-2030)
Figure 41. Mexico Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Brazil Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Argentina Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Colombia Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Middle East and Africa Oral GLP-1 Agonist Sales Market Share by Country (2019-2030)
Figure 46. Middle East and Africa Oral GLP-1 Agonist Revenue Market Share by Country (2019-2030)
Figure 47. Turkey Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. UAE Oral GLP-1 Agonist Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Global Sales Market Share of Oral GLP-1 Agonist by Type (2019-2030)
Figure 51. Global Revenue Market Share of Oral GLP-1 Agonist by Type (2019-2030)
Figure 52. Global Oral GLP-1 Agonist Price (US$/Unit) by Type (2019-2030)
Figure 53. Global Sales Market Share of Oral GLP-1 Agonist by Application (2019-2030)
Figure 54. Global Revenue Market Share of Oral GLP-1 Agonist by Application (2019-2030)
Figure 55. Global Oral GLP-1 Agonist Price (US$/Unit) by Application (2019-2030)
Figure 56. Oral GLP-1 Agonist Value Chain
Figure 57. Oral GLP-1 Agonist Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
